Myopia prevention and control
Conditions
Interventions
Experimental Group 1:single vision + 20h telescope
Experimental Group 2:Defocus + 20h telescope
Control Group:Defocus only
Sponsors
Beijing Tongren Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1: The refractive status meets the following conditions: - After ciliary muscle paralysis, computerized refraction testing yields equivalent spherical power between -0.50D and -6.00D (inclusive) for both eyes. - After ciliary muscle paralysis, computerized refraction testing shows astigmatism =1.5D for both eyes. - After ciliary muscle paralysis, computerized refraction testing indicates refractive anisometropia =1.5D for both eyes. 2: IOP =21mmHg for both eyes. 3: Best corrected visual acuity is greater than or equal to 1.0 for both eyes. 4: The parent/guardian understands the protocol and is willing to enroll the participant in the randomized groups for hyperbolic surface telescope myopia intervention. 5: The patient understands and voluntarily agrees to participate in this study, and the informed consent form is signed by both the patient and the parent/guardian. 6: 6 = Age = 12 years old, gender unlimited.
Exclusion criteria
Exclusion criteria: 1: Allergic to the mydriatic drugs or their components used in this study. 2: Abnormalities in the refractive system of either eye, such as keratoconus, lenticonus, or spherophakia 3: Diseases that may affect refractive development or progress to high myopia, such as Down syndrome, Marfan syndrome, retinopathy of prematurity, and neonatal ischemic-hypoxic encephalopathy 4: Any eye with other ocular abnormalities or diseases affecting vision, such as ptosis, congenital corneal abnormalities, corneal leukoma, congenital lens abnormalities, cataract, macular lesions, choroidal lesions, severe vitreous opacity, or retinal disease 5: A history of glaucoma and/or shallow anterior chamber in either eye 6: History of manifest strabismus, amblyopia, or nystagmus, either past or present 7: History of eyelid, strabismus, intraocular, or refractive surgery, either past or present 8: Use of medications affecting efficacy evaluation systemically or locally within the 3 months prior to screening, such as anticholinergic drugs (e.g., atropine, tropicamide), antimuscarinic drugs (e.g., scopolamine), or drugs affecting pupil size and accommodation (e.g., belladonna extract, morphine, sedative-hypnotics) 9: Use of myopia control methods within the past month, including atropine or other antimuscarinic drugs, dual-focus/progressive or multifocal contact lenses, dual-focus/progressive or multifocal spectacle frames, corneal shaping lenses, rigid gas-permeable or other corneal contact lenses intended to reduce myopia progression 10: Past or present systemic diseases, including autoimmune diseases, central nervous system diseases, asthma, diabetes, severe cardiopulmonary dysfunction, severe hepatic or renal impairment 11: Clear family history of high myopia 12: Participation in other clinical trials within the month prior to randomization 13: Investigator's judgment that there are any other inappropriate conditions for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diopter;Axis oculi; | — |
Countries
China
Contacts
Public ContactLei Tian
Beijing Tongren Hospital Affiliated to Capital Medical University
Outcome results
None listed